BACKGROUND: Ranolazine (Ran) is known to inhibit multiple targets, including the late Na(+)current, the rapid delayed rectifying K(+)current, the L-type Ca(2+)current, and fatty acid metabolism. Functionally, Ran suppresses early afterdepolarization (EADs) and torsades de pointes (TdP) in drug-induced long QT type 2 (LQT2) presumably by decreasing intracellular [Na(+)](i) and Ca(2+)overload. However, simulations of EADs in LQT2 failed to predict their suppression by Ran. OBJECTIVE: To elucidate the mechanism(s) whereby Ran alters cardiac action potentials (APs) and cytosolic Ca(2+)transients and suppresses EADs and TdP in LQT2. METHODS: The known effects of Ran were included in simulations (Shannon and Mahajan models) of rabbit ventricular APs and Ca(2+)transients in control and LQT2 models and compared with experimental optical mapping data from Langendorff rabbit hearts treated with E4031 (0.5 μM) to block the rapid delayed rectifying K(+)current. Direct effects of Ran on cardiac ryanodine receptors (RyR2) were investigated in single channels and changes in Ca(2+)-dependent high-affinity ryanodine binding. RESULTS: Ran (10 μM) alone prolonged action potential durations (206 ± 4.6 to 240 ± 7.8 ms; P <0.05); E4031 prolonged action potential durations (204 ± 6 to 546 ± 35 ms; P <0.05) and elicited EADs and TdP that were suppressed by Ran (10 μM; n = 7 of 7 hearts). Simulations (Shannon but not Mahajan model) closely reproduced experimental data except for EAD suppression by Ran. Ran reduced open probability (P(o)) of RyR2 (half maximal inhibitory concentration = 10 ± 3 μM; n = 7) in bilayers and shifted half maximal effective concentration for Ca(2+)-dependent ryanodine binding from 0.42 ± 0.02 to 0.64 ± 0.02 μM with 30 μM Ran. CONCLUSIONS: Ran reduces P(o) of RyR2, desensitizes Ca(2+)-dependent RyR2 activation, and inhibits Ca(i) oscillations, which represents a novel mechanism for its suppression of EADs and TdP.
BACKGROUND:Ranolazine (Ran) is known to inhibit multiple targets, including the late Na(+)current, the rapid delayed rectifying K(+)current, the L-type Ca(2+)current, and fatty acid metabolism. Functionally, Ran suppresses early afterdepolarization (EADs) and torsades de pointes (TdP) in drug-induced long QT type 2 (LQT2) presumably by decreasing intracellular [Na(+)](i) and Ca(2+)overload. However, simulations of EADs in LQT2 failed to predict their suppression by Ran. OBJECTIVE: To elucidate the mechanism(s) whereby Ran alters cardiac action potentials (APs) and cytosolic Ca(2+)transients and suppresses EADs and TdP in LQT2. METHODS: The known effects of Ran were included in simulations (Shannon and Mahajan models) of rabbit ventricular APs and Ca(2+)transients in control and LQT2 models and compared with experimental optical mapping data from Langendorff rabbit hearts treated with E4031 (0.5 μM) to block the rapid delayed rectifying K(+)current. Direct effects of Ran on cardiac ryanodine receptors (RyR2) were investigated in single channels and changes in Ca(2+)-dependent high-affinity ryanodine binding. RESULTS:Ran (10 μM) alone prolonged action potential durations (206 ± 4.6 to 240 ± 7.8 ms; P <0.05); E4031 prolonged action potential durations (204 ± 6 to 546 ± 35 ms; P <0.05) and elicited EADs and TdP that were suppressed by Ran (10 μM; n = 7 of 7 hearts). Simulations (Shannon but not Mahajan model) closely reproduced experimental data except for EAD suppression by Ran. Ran reduced open probability (P(o)) of RyR2 (half maximal inhibitory concentration = 10 ± 3 μM; n = 7) in bilayers and shifted half maximal effective concentration for Ca(2+)-dependent ryanodine binding from 0.42 ± 0.02 to 0.64 ± 0.02 μM with 30 μM Ran. CONCLUSIONS:Ran reduces P(o) of RyR2, desensitizes Ca(2+)-dependent RyR2 activation, and inhibits Ca(i) oscillations, which represents a novel mechanism for its suppression of EADs and TdP.
Authors: P G Volders; M A Vos; B Szabo; K R Sipido; S H de Groot; A P Gorgels; H J Wellens; R Lazzara Journal: Cardiovasc Res Date: 2000-06 Impact factor: 10.787
Authors: Fredrick A Hilliard; Derek S Steele; Derek Laver; Zhaokang Yang; Sylvain J Le Marchand; Nagesh Chopra; David W Piston; Sabine Huke; Björn C Knollmann Journal: J Mol Cell Cardiol Date: 2009-10-14 Impact factor: 5.000
Authors: Charles Antzelevitch; Luiz Belardinelli; Lin Wu; Heather Fraser; Andrew C Zygmunt; Alexander Burashnikov; José M Di Diego; Jeffrey M Fish; Jonathan M Cordeiro; Robert J Goodrow; Fabiana Scornik; Guillermo Perez Journal: J Cardiovasc Pharmacol Ther Date: 2004-09 Impact factor: 2.457
Authors: Carl Sims; Steven Reisenweber; Prakash C Viswanathan; Bum-Rak Choi; William H Walker; Guy Salama Journal: Circ Res Date: 2008-04-24 Impact factor: 17.367
Authors: Hani N Sabbah; Margaret P Chandler; Takayuki Mishima; George Suzuki; Pervaiz Chaudhry; Omar Nass; Brandon J Biesiadecki; Brent Blackburn; Andrew Wolff; William C Stanley Journal: J Card Fail Date: 2002-12 Impact factor: 5.712
Authors: Jiali Nie; Quanlu Duan; Mengying He; Xianqing Li; Bei Wang; Chi Zhou; Lujin Wu; Zheng Wen; Chen Chen; Dao Wu Wang; Katherina M Alsina; Xander H T Wehrens; Dao Wen Wang; Li Ni Journal: J Cell Physiol Date: 2018-11-29 Impact factor: 6.384
Authors: Jennifer L Smith; Allison R Reloj; Parvathi S Nataraj; Daniel C Bartos; Elizabeth A Schroder; Arthur J Moss; Seiko Ohno; Minoru Horie; Corey L Anderson; Craig T January; Brian P Delisle Journal: Am J Physiol Cell Physiol Date: 2013-07-17 Impact factor: 4.249
Authors: Gary L Aistrup; Deepak K Gupta; James E Kelly; Matthew J O'Toole; Amanda Nahhas; Nimi Chirayil; Sol Misener; Lauren Beussink; Neha Singh; Jason Ng; Mahendra Reddy; Thitipong Mongkolrattanothai; Nesrine El-Bizri; Sridharan Rajamani; John C Shryock; Luiz Belardinelli; Sanjiv J Shah; J Andrew Wasserstrom Journal: Am J Physiol Heart Circ Physiol Date: 2013-07-19 Impact factor: 4.733
Authors: Mitsunori Maruyama; Jianmin Xiao; Qiang Zhou; Kannan Vembaiyan; Su-Kiat Chua; Michael Rubart-von der Lohe; Shien-Fong Lin; Thomas G Back; S R Wayne Chen; Peng-Sheng Chen Journal: Heart Rhythm Date: 2012-09-14 Impact factor: 6.343